Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02855229 · ClinicalTrials.gov registry record
Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains
A clinical trial of Translational Electrophysiology, sponsored by Mclean Hospital.
- Completed
- Registry status
- 222
- Enrollment target
- 1
- Study location
NCT02855229: Completed study of Translational Electrophysiology, sponsored by Mclean Hospital.
NCT02855229 is a study of Translational Electrophysiology that has completed, run by Mclean Hospital. The registered enrollment target is 222 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02855229, a study of Translational Electrophysiology, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- 222 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of this multi-disciplinary research program is to develop and optimize new cross-species translational assessments of reward and cognition that will not only be assessed in parallel in humans and rats, but also produce neurophysiological and behavioral metrics that can be objectively compared across species. The research will build on prior studies by further developing and optimizing (in Phase 1), then validating via pharmacological challenge (in Phase 2), the following assays in both humans and rats: 1. advanced neurophysiological and computational modeling techniques to record and analyze EEG activity within and across species; and 2. behavioral assessments of reward learning, cognitive control, and cognitive flexibility will be analyzed within and across species. The second phase of the study will test the translational validity of these assays, by assessing the impact of a targeted drug on task performance and EEG activity in both species.
Primary Outcome
Relative FRP response is the primary outcome measure for the probabilistic reward task (PRT) used in Phase 1.
Conditions Studied
Interventions
- DRUG Methylphenidate
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2020-08-15 |
| Est. Completion | 2021-08-31 |
What the finished NCT02855229 record still lists
NCT02855229 is an observational study that tracks outcomes without assigning an intervention. The registered 222 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Translational Electrophysiology appearing as the primary indexed condition, and to 1 intervention - of which Methylphenidate is the first listed.
NCT02855229 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02855229 about?
NCT02855229 is a clinical study titled "Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains". The overarching goal of this multi-disciplinary research program is to develop and optimize new cross-species translational assessments of reward and cognition that will not only be assessed in parallel in humans and rats, but also produce neurophysiological and behavioral metrics that can be object...
What is the current status of trial NCT02855229?
This trial is currently completed. The enrollment target is 222 participants. The study started on 2020-08-15. Estimated completion is 2021-08-31.
What conditions does trial NCT02855229 study?
This clinical trial studies the following conditions: Translational Electrophysiology.
What interventions are being tested in trial NCT02855229?
The interventions under investigation include: Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT02855229?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02855229 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
- NCT05605574 · 222 participants · NA
Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI